Natera, Inc. $NTRA Shares Purchased by GDS Wealth Management

Key Points

• GDS Wealth Management significantly increased its holdings in Natera, Inc. by 325.9% in Q1, owning 53,086 shares valued at approximately $7.5 million after purchasing an additional 40,623 shares.
• Natera reported a revenue of $546.60 million for the latest quarter, surpassing analyst estimates of $476.84 million, although it missed earnings per share estimates.
• Analysts have a consensus rating of "Buy" on Natera, with an average price target of $193.19, reflecting strong interest from institutional investors.

GDS Wealth Management lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 325.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,086 shares of the medical research company's stock after acquiring an additional 40,623 shares during the period. GDS Wealth Management's holdings in Natera were worth $7,507,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after acquiring an additional 77,357 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after acquiring an additional 660,538 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the last quarter. Invesco Ltd. grew its position in Natera by 13.7% in the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after buying an additional 245,719 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its position in Natera by 5.6% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock valued at $215,127,000 after buying an additional 80,865 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 6,111 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the completion of the transaction, the chief executive officer owned 179,071 shares of the company's stock, valued at $28,132,054.10. This represents a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,792 shares of company stock worth $9,227,972. Company insiders own 5.63% of the company's stock.

Natera Price Performance

Shares of NASDAQ NTRA traded up $3.65 during trading on Friday, hitting $165.60. 839,847 shares of the company were exchanged, compared to its average volume of 1,655,524. The company has a market cap of $22.73 billion, a price-to-earnings ratio of -86.70 and a beta of 1.76. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The firm's fifty day moving average price is $154.85 and its 200 day moving average price is $154.16.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Natera's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NTRA shares. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Piper Sandler reiterated an "overweight" rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. UBS Group lifted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Cowen reiterated a "buy" rating on shares of Natera in a research report on Friday, August 8th. Finally, Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $193.19.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.